KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial.

Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui

J Eur Acad Dermatol Venereol 40(5) 887-899

PMID41239899
PMCIDPMC13109765
DOI10.1111/jdv.70156
发表日期2025-11-15
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: The efficacy and safety of brodalumab in Japanese patients with palmoplantar pustulosis (PPP) were demonstrated during the 16-week double-blind phase of a randomized controlled trial. However, long-term data are unavailable. OBJECTIVES: To assess the efficacy and safety of brodalumab 210 mg administered subcutaneously (SC) repeatedly until Week 68 in PPP patients with moderate or severe pustules/vesicles in an open-label extension study. METHODS: In a multicentre, Phase 3, randomized, double-blind, placebo-controlled trial, Japanese adults having a diagnosis of PPP for ≥24 weeks, PPP Area Severity Index (PPPASI) of ≥12, PPPASI subscore of pustules/vesicles of ≥2 and inadequate response to therapy were included. Patients completing the double-blind phase with brodalumab 210 mg or placebo (1:1) SC once every 2 weeks (Q2W) for 16 weeks were invited to enter the open-label extension to receive brodalumab for the subsequent 52 weeks. RESULTS: By Week 68, 35 patients in the brodalumab group and 43 patients in the placebo-to-brodalumab group completed the study, with discontinuations (28 and 20 patients, respectively) primarily due to patient withdrawal. At Week 68, the mean ± SD improvement of the PPPASI total score from baseline was 23.83 ± 12.28 and 22.37 ± 13.09 in the brodalumab and placebo-to-brodalumab groups, respectively. Continued improvement or trend for improvement was seen in the secondary endpoints such as PPPASI 50/75/90 responses and Dermatology Life Quality Index. The incidence of adverse events was 849.3/100 person-years. Otitis externa had the highest incidence (44.0/100 person-years; Grade 1 or 2 only). Infection-related events were frequent but controllable. CONCLUSIONS: Brodalumab SC 210 mg Q2W administered for 68 weeks showed a long-term benefit to both dermatological and quality of life indices in these patients. It is expected to be used in appropriate patients, considering both safety risks and efficacy benefits.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Study design. Modified from the figure published in the supplementary section for results up to 16 weeks. D, day; EOS, end of study; Q2W, once every 2 weeks; SC, subcutaneous; W, week.
非 KM Figure
FIGURE 2FIGURE 2 Participant flow. One patient randomized to receive placebo was excluded from all the subsequent analyses (demographic, efficacy and safety) because the patient had not provided consent as specified in the protocol, which was considered as a deviation from GCP. Modified from the figure published for the results up to 16 weeks. GCP, Good Clinical Practice; PHQ‐8, eight‐item Patient Health Questionnaire depression scale.
非 KM Figure
FIGURE 3FIGURE 3 Summary of change from baseline in PPPASI and PPP‐SI total score. (a) PPPASI total score; (b) PPP‐SI total score. The brodalumab group included 63, 50 and 35 patients at Weeks 2, 16 and 68 respectively. The placebo‐to‐brodalumab group (brodalumab was administered after Week 16) included 62, 62 and 43 patients, respectively. Error bars indicate SD. BOCF, baseline observation carried forward; PPPASI, palmoplantar pustulosis Area Severity Index; PPP‐SI, palmoplantar pustulosis Severity Index. *Indicates n for observations by BOCF approach for Weeks 16 and 68, shown using triangle markers in the graph.
非 KM Figure
FIGURE 4FIGURE 4 Summary of change from baseline in DLQI and PGA 0/1 response. (a) DLQI total score. (b) Proportion of patients who achieved PGA 0/1 response. The brodalumab group included 63, 50 and 35 patients at Weeks 2, 16 and 68, respectively. The placebo‐to‐brodalumab group (brodalumab was administered after week 16) included 62, 62 and 43 patients, respectively. Error bars indicate SD in (a) and 95% confidence interval in (b). BOCF, baseline observation carried forward; DLQI, Dermatology Life Quality Index; PGA, Physician's Global Assessment. *Indicates n for observations by BOCF approach for Weeks 16 and 68, shown using triangle markers in the graph.
非 KM Figure